Nassim Usman, Catalyst Biosciences CEO

Af­ter $60M Ver­tex deal, group of Cat­a­lyst share­hold­ers claims biotech could’ve sold as­sets three years ago

Cat­a­lyst Bio­sciences was down to five em­ploy­ees in March, and the biotech need­ed to do some­thing af­ter two rounds of lay­offs, a nixed col­lab­o­ra­tion and a culling of its he­mo­phil­ia pro­gram.

In came Ver­tex, with $60 mil­lion to buy up the South San Fran­cis­co biotech’s pre­clin­i­cal com­ple­ment drugs, which tar­get the sys­tem that bridges the body’s in­nate and adap­tive im­mune re­sponse and a class most known for Ul­tomiris and Soliris. The deal in­cludes CB 2782-PEG, the dry AMD drug that Bio­gen no longer want­ed in March.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.